UPDATED: Galapagos CEO Paul Stoffels bets €225M on a new CAR-T strategy for the long suffering biotech
The deeply troubled European biotech Galapagos and its new CEO Paul Stoffels are going the CAR-T route, and they have a new, €225 million buyout designed to give them an inside track over the first-gen therapies that have made their way into the market.
Just weeks after inking an exclusive licensing pact for an anti-BCMA CAR-T out of China, Dutch biotech CellPoint has struck a deal to sell the company to Galapagos, with €125 million coming in cash and another €100 million on the table for potential milestones.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.